MARKET

FENC

FENC

Fennec Pharmaceuticals Inc
NASDAQ
10.20
-0.13
-1.26%
After Hours: 10.20 0 0.00% 19:30 10/02 EDT
OPEN
10.46
PREV CLOSE
10.33
HIGH
10.49
LOW
10.03
VOLUME
136.44K
TURNOVER
--
52 WEEK HIGH
13.25
52 WEEK LOW
5.65
MARKET CAP
357.69M
P/E (TTM)
-87.4786
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at FENC last week (0921-0925)?
Weekly Report · 5d ago
Weekly Report: what happened at FENC last week (0914-0918)?
Weekly Report · 09/21 09:14
Fennec’s Pedmark Trial in Japan Shows Strong Hearing Protection Without Hurting Tumor Response
TipRanks · 09/17 13:47
Fennec presents results from STS-J01 clinical trial evaluating Pedmark
TipRanks · 09/17 11:35
Weekly Report: what happened at FENC last week (0907-0911)?
Weekly Report · 09/14 09:15
Fennec Pharmaceuticals Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Dow Jones · 09/09 11:28
Analyst Reaffirms Buy on Fennec’s PEDMARK Momentum and Growth Catalysts, Maintains $16 12-Month Target
TipRanks · 09/09 10:55
Weekly Report: what happened at FENC last week (0831-0904)?
Weekly Report · 09/07 09:14
More
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Webull offers Fennec Pharmaceuticals Inc stock information, including NASDAQ: FENC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FENC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FENC stock methods without spending real money on the virtual paper trading platform.